Modeling codelivery of CD73 inhibitor and dendritic cell-based vaccines in cancer immunotherapy.
Sign Up to like & getrecommendations! Published in 2021 at "Computational biology and chemistry"
DOI: 10.1016/j.compbiolchem.2021.107585
Abstract: Dendritic cells (DCs) are the dominant class of antigen-presenting cells in humans; therefore, a range of DC-based approaches have been established to promote an immune response against cancer cells. The efficacy of DC-based immunotherapeutic approaches… read more here.
Keywords: immunotherapy; cd73 inhibitor; codelivery cd73; model ... See more keywords
Orally Bioavailable Small Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression Through Blockade of Adenosine Production.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.0c01086
Abstract: The adenosinergic pathway represents an attractive new therapeutic approach in cancer immunotherapy. In this pathway, ecto-5-nucleotidase CD73 has the unique function of regulating production of immunosuppressive adenosine (ADO) through the hydrolysis of AMP. CD73 is… read more here.
Keywords: orally bioavailable; production; cd73 inhibitor; small molecule ... See more keywords
Abstract 5258: Preclinical testing of CD73 inhibitor AB680 for pancreatic cancer immunoprevention
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5258
Abstract: Introduction: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a profoundly immunosuppressive microenvironment. Innovative therapeutic strategies are urgently needed to stop the progression of precancerous lesions into aggressive PDAC, which remains a lethal malignancy. The goal… read more here.
Keywords: ab680 treated; treated mice; pdac; cd73 inhibitor ... See more keywords